Rules Body 'Will Limit New Drugs'

Monday, February 20th 2006

• Tweet

The Government's drug-buying agency warns that a new trans-Tasman regulatory body will favour the industry at the expense of New Zealanders' access to medicines and "to the detriment of patient safety".

The January memo to Pharmac's board also warned of a "massive escalation" in the cost of registering generic or cheap drugs - from $8000 to more than $100,000 an approval.

Cost increases by the new joint therapeutics agency would be passed on to consumers or limit the range of medicines that companies would be prepared to register in New Zealand, the memo said.

The warnings have horrifies Green and National MP's.

The memo, obtained by the Greens under the Official Information Act, has reinforced concerns about the impact of the new agency.

In December, concern was raised about how it would hit the $200 million-a-year supplements and alternatives industry.

That month New Zealand and Australian Governments agreed to establish the agency from July 1 next year, although legislation is also required.

Yesterday, the health select committee finalised a report examining the agreement.

It will be tabled in Parliament today.

All other political parties have expressed concern about the matter, potentially embarrassing the Government as it tries to get the numbers to pass the legislation.

The memo said the "massive escalation" in the cost of registration could result in a "dramatic change in the viability of some products, resulting ultimately in companies not bringing them into the market".

The risk of a user-pays agency was that regulatory decisions would favour the drug industry "at the expense of New Zealanders access to medicines, and to the detriment of patient safety".

Health Minister Annette King referred the Herald's questions to the Ministry of Health.

The agency project team leader, Susan Martindale, rejected Pharmac's claims.

"I don't see that we are talking about a risk of detriment to New Zealanders' access to medicines."

A properly resources agency, she said, could provide quicker access to innovative new medicines then now.

Dr Martindale said drug registration fees would rise even without the new agency, as they were set in 1991 and no longer covered costs.

She said Pharmac was wrong in saying generic drug approvals in Australia cost more than $100,000. The cost was about $65,000.

Green MP Sue Kedgley said the memo proved everything the greens had been saying.

"It calls into question why on earth we would consider going into this joint agency," she said.

"Serious questions need to be asked about why the Government seemed hellbent on joining the agency when it is clearly not in the national interest of New Zealand to do so.

"Is there some hidden agenda here, or have officials advising the Government failed to properly inform the Government about the real risks of joining an agency?"

National's associate health spokesman, Paul Hutchison, said he was surprised and worried by the memo's tone and content.

Source New Zealand Herald, 17 June 2004

Footnote from Ideal Health

Related articles can be found here:

Alternative Therapies May Be Integrated By Government

Bitter pill: Govt surrenders $200m industry to Australian control

British Health Stores Face Closure

Bureaucratic Waste Plagues U.S. Healthcare

Complementary Health Response Disappoints Sue Kedgley

Govt Suffers Setback on Trans-Tasman Plans

Industry Not Motivated to Study Drug-Herb Interactions

NZ Health Trust Newsletter

Pharmaceutical Vitamin Price Fixing Exposed

Pharmac Warns Huge Fees Will Price Medicines Off the Shelf

SPEECH - ALLISON ROE, JUNE 16TH 2006

Speech by Green Health spokesperson Sue Kedgley to the Natural Healthcare Policy Debate

US Government Warns Drugmakers on Illegal Kickbacks

If you need help or advice, you are welcome to email our naturopathic team with your health question.

Disclaimer: The health information presented here has been written for the New Zealand health consumer. It is of a general nature and is only intended to provide a summary of the subjects covered. The information is not intended to be comprehensive or to provide medical advice to you. While all care has been taken to ensure the accuracy of the information, no responsibility or liability is accepted, and no person should act in reliance on any statement contained in the information provided. All health ailments should be treated by a qualified health professional.

ref:n353

• Tweet